BioCentury
ARTICLE | Clinical News

BL-8020: Phase I/II started

May 6, 2013 7:00 AM UTC

BioLineRx began an open-label, French Phase I/II trial to evaluate once-daily 575 mg BL-8020 plus ribavirin for 16 weeks in up to 32 HCV patients who failed or relapsed following treatment with standa...